Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB has initiated a project to build in-house biotech microbial manufacturing capacity in Bulle, Switzerland to secure demand for its core product Cimzia (certoluzimab pegol).
Subscribe to our email newsletter
The company said that the new manufacturing unit is expected to be operational in 2015 and requires an investment of EUR250m in two steps.
UCB Technical Operations & Quality VP Michele Antonelli said that they want to be able to meet their projected future demand for 2015 and beyond for Cimzia – by adding internal capacity to the existing capacities with their productions partners.
"Our site in Bulle is the right place and most cost effective location to build our own biotech manufacturing unit which enables us to further improve our productivity at attractive terms," Antonelli said.
"The new unit together with the bio-pilot-plant under construction in Braine l’Alleud, Belgium will also strengthen our ability to deliver our future biological products."